Rizzo S
Int J Clin Pharmacol Res. 1986;6(3):225-30.
In a double-blind study, 50 patients with chronic persistent hepatitis were assigned at random to two treatment groups. One group was given arginine tidiacicate (ATCA) at the dose of 400 mg tablets three times a day and the other given a placebo, both for 30 days. The group of patients receiving ATCA showed a clear-cut improvement of subjective symptoms and of the most important cytolysis and cholestasis parameters studied, such modifications being greater than in the placebo group. Drug tolerance was excellent, since no side-effects were observed.
在一项双盲研究中，50例慢性持续性肝炎患者被随机分为两个治疗组。一组患者每日三次服用剂量为400毫克片剂的精氨酸替地卡酯（ATCA），另一组服用安慰剂，疗程均为30天。接受ATCA治疗的患者组主观症状以及所研究的最重要的细胞溶解和胆汁淤积参数均有明显改善，这些改善大于安慰剂组。药物耐受性良好，因为未观察到副作用。
